Next Article in Journal
Alkaloid Profiling, Anti-Enzymatic and Antiproliferative Activity of the Endemic Chilean Amaryllidaceae Phycella cyrtanthoides
Previous Article in Journal
Environmental Metabolomics Promises and Achievements in the Field of Aquatic Ecotoxicology: Viewed through the Pharmaceutical Lens
Previous Article in Special Issue
Plasma Metabolite Markers of Parkinson’s Disease and Atypical Parkinsonism
Article

Human Brain Lipidomics: Pilot Analysis of the Basal Ganglia Sphingolipidome in Parkinson’s Disease and Lewy Body Disease

1
Anatomy Department, DeBusk College of Osteopathic Medicine, Lincoln Memorial University, Cumberland Gap Pkwy, Harrogate, TN 37752, USA
2
Department of Neurology, Oregon Health & Science University, Portland, OR 97239, USA
3
Metabolomics Unit, College of Veterinary Medicine, Lincoln Memorial University, Cumberland Gap Pkwy, Harrogate, TN 37752, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Amedeo Lonardo and Peter Meikle
Metabolites 2022, 12(2), 187; https://doi.org/10.3390/metabo12020187
Received: 14 December 2021 / Revised: 1 February 2022 / Accepted: 3 February 2022 / Published: 18 February 2022
Sphingolipids constitute a complex class of bioactive lipids with diverse structural and functional roles in neural tissue. Lipidomic techniques continue to provide evidence for their association in neurological diseases, including Parkinson’s disease (PD) and Lewy body disease (LBD). However, prior studies have primarily focused on biological tissues outside of the basal ganglia, despite the known relevancy of this brain region in motor and cognitive dysfunction associated with PD and LBD. Therefore electrospray ionization high resolution mass spectrometry was used to analyze levels of sphingolipid species, including ceramides (Cer), dihydroceramides (DHC), hydoxyceramides (OH-Cer), phytoceramides (Phyto-Cer), phosphoethanolamine ceramides (PE-Cer), sphingomyelins (SM), and sulfatides (Sulf) in the caudate, putamen and globus pallidus of PD (n = 7) and LBD (n = 14) human subjects and were compared to healthy controls (n = 9). The most dramatic alterations were seen in the putamen, with depletion of Cer and elevation of Sulf observed in both groups, with additional depletion of OH-Cer and elevation of DHC identified in LBD subjects. Diverging levels of DHC in the caudate suggest differing roles of this lipid in PD and LBD pathogenesis. These sphingolipid alterations in PD and LBD provide evidence for biochemical involvement of the neuronal cell death that characterize these conditions. View Full-Text
Keywords: ceramide; dihydroceramide; sphingomyelin; sulfatide; sphingolipid; alpha synuclein; striatum; globus pallidus ceramide; dihydroceramide; sphingomyelin; sulfatide; sphingolipid; alpha synuclein; striatum; globus pallidus
Show Figures

Figure 1

MDPI and ACS Style

Beger, A.W.; Dudzik, B.; Woltjer, R.L.; Wood, P.L. Human Brain Lipidomics: Pilot Analysis of the Basal Ganglia Sphingolipidome in Parkinson’s Disease and Lewy Body Disease. Metabolites 2022, 12, 187. https://doi.org/10.3390/metabo12020187

AMA Style

Beger AW, Dudzik B, Woltjer RL, Wood PL. Human Brain Lipidomics: Pilot Analysis of the Basal Ganglia Sphingolipidome in Parkinson’s Disease and Lewy Body Disease. Metabolites. 2022; 12(2):187. https://doi.org/10.3390/metabo12020187

Chicago/Turabian Style

Beger, Aaron W., Beatrix Dudzik, Randall L. Woltjer, and Paul L. Wood. 2022. "Human Brain Lipidomics: Pilot Analysis of the Basal Ganglia Sphingolipidome in Parkinson’s Disease and Lewy Body Disease" Metabolites 12, no. 2: 187. https://doi.org/10.3390/metabo12020187

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop